Scarica l'app Stockscreener
196.52
0.52%
1.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
LSV Asset Management Grows Position in Biogen Inc. $BIIB - MarketBeat
Clinically Isolated Syndrome Treatment Market Size 2030 US$ 2.4 - openPR.com
BIIB: Late-stage lupus therapies and a diverse immunology pipeline target major unmet needs - TradingView
Biogen Spotlights Lupus Pipeline at Piper Sandler Symposium: Litifilimab, Dapirolizumab in Focus - Yahoo Finance
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178 – Here’s Why - Insider Monkey
Wedbush Lifts PT on Biogen Inc. (BIIB) to $187 From $178Here's Why - Finviz
Is Biogen (NASDAQ:BIIB) Using Too Much Debt? - 富途牛牛
There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings - simplywall.st
Krilogy Financial LLC Invests $1.18 Million in Biogen Inc. $BIIB - MarketBeat
Biogen's (NASDAQ:BIIB) Soft Earnings Don't Show The Whole Picture - Yahoo Finance
The 5 Most Interesting Analyst Questions From Biogen's Q4 Earnings Call - Finviz
Biogen Inc. $BIIB Shares Sold by Illinois Municipal Retirement Fund - MarketBeat
Maria Freire to replace Caroline Dorsa as Biogen chair - The Pharma Letter
Leuthold Group LLC Acquires New Shares in Biogen Inc. $BIIB - MarketBeat
Stargardt Disease Therapeutics Market to Hit US$1,385.6M - openPR.com
Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap… - marketscreener.com
The 5 Most Interesting Analyst Questions From Biogen’s Q4 Earnings Call - The Globe and Mail
Biogen Inc. (BIIB) Announces Leadership Transition in Board of D - GuruFocus
Biogen’s profit forecast tops estimates on cost-cutting - MSN
Biogen (BIIB) Valuation Check After Q4 Beat And Momentum In New Drugs Like Leqembi - simplywall.st
FMR LLC's Strategic Acquisition of Biogen Inc Shares - GuruFocus
Biogen Beats Pharmacies' MS Drug Monopoly Suit, For Now - Law360
Biogen (BIIB) Appoints Maria Freire as Upcoming Chair of Board - GuruFocus
Biogen Announces Board Chair Caroline Dorsa to Step Down - TipRanks
Biogen Announces Board Chair Transition - Biogen
Biogen (NASDAQ:BIIB) Price Target Raised to $236.00 - MarketBeat
Biogen Is Repositioning Its Portfolio to Partly Offset Ongoing Revenue Declines - Morningstar
Trading Systems Reacting to (BIIB) Volatility - Stock Traders Daily
Biogen (NASDAQ:BIIB) Insider Priya Singhal Sells 2,660 Shares - MarketBeat
Biogen Inc (BIIB) Insider Priya Singhal Sells 2,660 Shares - GuruFocus
Key facts: Biogen's LEQEMBI gets Priority Review in China; Wedbush raises price target - TradingView
BIIB: Wedbush Raises Price Target to $187 While Maintaining Neut - GuruFocus
Mizuho Raises Price Target on Biogen to $236 From $207, Keeps Outperform Rating - marketscreener.com
Biogen Pipeline Advances In Lupus And SMA Reshape Growth Outlook - Yahoo Finance
State of Michigan Retirement System Has $6.04 Million Position in Biogen Inc. $BIIB - MarketBeat
Why Biogen (BIIB) Is Up 8.2% After Mixed 2025 Earnings and Neurology Pipeline Updates – And What's Next - Yahoo Finance
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China - JCN Newswire
Analyst JP Morgan Raises Price Target for Biogen (BIIB) to $230 - GuruFocus
Biogen Refocuses On High-Need Neurology As New Drugs Reach Inflection Point - simplywall.st
Biogen (BIIB) Sees Raised Price Target by Canaccord Genuity | BI - GuruFocus
Key facts: Analysts Boost Biogen Price Targets; Profit Outlook Improves; Leqembi Review Accelerated - TradingView
BIIB: BMO Capital Elevates Price Target While Maintaining Market Perform Rating | BIIB Stock News - GuruFocus
Analysts Offer Insights on Healthcare Companies: Centene (CNC) and Biogen (BIIB) - The Globe and Mail
Biogen (BIIB) Analyst Rating Update: Citigroup Raises Price Targ - GuruFocus
BIIB Analysts Maintain Rating, Significant Price Target Increase by TD Cowen | BIIB Stock News - GuruFocus
Biogen (NASDAQ:BIIB) Price Target Raised to $215.00 - MarketBeat
Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says - marketscreener.com
Guggenheim Raises Price Target on Biogen (BIIB) to $246 | BIIB S - GuruFocus
Goldman Sachs reiterates Buy rating on Biogen stock amid Leqembi growth - Investing.com
BMO Capital raises Biogen stock price target to $196 on Spinraza potential - Investing.com
BIIB: RBC Capital Increases Biogen's Price Target to $233 on Sus - GuruFocus
Biogen Posts Q4 Beat, Analysts Raise Price Targets On 'Significant Pipeline Diversification' - Benzinga
Piper Sandler Raises Price Target for Biogen (BIIB) to $177 | BI - GuruFocus
Wells Fargo Raises Biogen (BIIB) Price Target to $200 | BIIB Sto - GuruFocus
Truist Securities Raises Price Target for Biogen (BIIB) to $193 | BIIB Stock News - GuruFocus
Biogen stock price target raised to $215 from $175 at TD Cowen - Investing.com
Biogen stock price target raised to $233 from $217 at RBC Capital - Investing.com
Piper Sandler raises Biogen stock price target to $177 on Leqembi ramp - Investing.com
Biogen’s much anticipated Tau readout in Alzheimer’s will spur more questions - PharmaLive
BIIB Stock Receives Raised Price Target from HC Wainwright & Co. - GuruFocus
Wedbush Raises Price Target on Biogen to $187 From $178, Keeps Neutral Rating - marketscreener.com
Truist Financial Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock - MarketBeat
Biogen’s Alisha Alaimo On The Company’s Next Big Commercial Build - Citeline News & Insights
Guggenheim raises Biogen stock price target to $246 on pipeline potential - Investing.com
Canaccord Genuity raises Biogen stock price target on strong Q4 results - Investing.com
Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings - Benzinga
Eli Lilly To Rally More Than 21%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
Biogen (NASDAQ:BIIB) Given New $187.00 Price Target at Wedbush - MarketBeat
RBC Raises Price Target on Biogen to $233 From $217, Keeps Outperform Rating - marketscreener.com
Biogen stock price target raised to $228 from $194 at H.C. Wainwright - Investing.com
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):